Form 4: Iovance Biotherapeutics Director Acquires Deferred Restricted Stock Units

Athena Countouriotis, a director of Iovance Biotherapeutics, acquired 49,303 deferred restricted stock units (DRSUs) on June 11, 2024, under the company's 2018 Equity Incentive Plan.

Summary

• On June 11, 2024, Athena Countouriotis, a director of Iovance Biotherapeutics, acquired 49,303 deferred restricted stock units (DRSUs).
• These DRSUs were granted under the Issuer's 2018 Equity Incentive Plan (as amended).
• Each DRSU represents a contingent right to receive one share of Iovance's common stock.
• The DRSUs will vest on the earlier of (i) the first anniversary of the transaction date or (ii) the day prior to the Issuer's next annual shareholder meeting, provided the Reporting Person continues to provide service to the Issuer on those dates.
• The issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock unit acquisition by a director, indicating alignment with the company's long-term performance but not necessarily a strong positive or negative signal.

Positives

• The acquisition of DRSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting and issuance of common stock are tied to future events, including continued service, resignation, change in control, or the passage of time.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their holdings of company stock.

Stakeholder Impact

• The acquisition of DRSUs by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates